Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

“…Previous studies showed that tolerability and hematologic AEs differed by schedule of panobinostat administration and that the MTD was not necessarily compatible with prolonged administration. 2 , 8 , 9 In our study, 22 patients (52%) received panobinostat for 1 year as scheduled (A: 10/21 patients, 52 vs B: 12/21, 57%), and seven of these (17%) required no dose interruptions or reductions. Reasons for premature discontinuation of study drug were AEs ( n =12), relapse ( n =5), patient decision ( n =2) or prohibited co-medication ( n =1).…”

Hematologic Response to Vorinostat Treatment in Relapsed Myeloid Leukemia of Down Syndrome

“…When used in combination, HDAC inhibitors can enhance the anticancer activity of those conventional agents by depriving malignant cells of prosurvival mechanisms, such as autophagy . A phase Ib/II trial in elderly acute myeloid leukemia patients successfully tested panobinostat in combination with cytarabine/idarubicin, demonstrating an increase in the complete remission rate from 55% to 64%, and relapse‐free survival from less than 9 months to 14 months . Although HDAC inhibitor therapies are generally well tolerated, future approaches in this context need to further reduce adverse side effects, of which nausea, fatigue, diarrhea, and thrombocytopenia are the most common …”

Leki wpływające na mechanizmy epigenetyczne w ostrej białaczce szpikowej

“…W innym badaniu Ocio i wsp. [96] oceniali skuteczność skojarzenia panobinostatu z klasycznym leczeniem indukcyjnym. Do badania włączono 38 chorych z medianą wieku 71 lat.…”